Serum thrombopoietin levels in patients undergoing autologous peripheral blood stem cell transplantation

Abstract

Summary:gated in patients receiving BMT and PBSCT. [5][6][7][8][9][10][11] A strong inverse correlation between serum granulocyte colony-stimulating factor (G-CSF) level and absolute neuRecently, the ligand for c-mpl has been cloned and initial studies have shown it to be the platelet regulatory trophil count has been demonstrated, 5-9 which suggests that G-CSF plays a critical role in the reconstitution of myeloid factor, thrombopoietin (TPO). To elucidate the role of TPO in the reconstitution of megakaryopoiesis and lineage progenitors after stem cell transplantation. However, of the growth factors studied, including interleukin-3 platelet production after stem cell transplantation, we measured serum TPO levels in nine patients undergoing (IL-3), interleukin-6 (IL-6) and leukemia inhibitory factor (LIF), none have been demonstrated to correlate with plateautologous peripheral blood stem cell transplantation (PBSCT) and in healthy volunteers. Serum TPO levels let recovery after stem cell transplantation. 6,9-11 A possible exception was reported by Testa et al 11 who showed that significantly correlated with the degree of peripheral thrombocytopenia and a strong inverse correlation peak IL-6 levels are directly correlated with the peak of platelet recovery. between serum TPO level and platelet count was observed (r = −0.700, P Ͻ 0.001). Serum TPO levels Recently, the ligand for c-mpl has been cloned; in vitro and in vivo studies have shown that it stimulates both began to rise as the platelet count decreased after chemotherapy. TPO levels peaked at over 25.00 megakaryocytopoiesis and platelet production, suggesting that it is the long-sought platelet regulatory factor, thromfmoles/ml between days 0 and 10; TPO levels then decreased gradually as the platelet count began to rise.bopoietin (TPO) itself. [12][13][14][15] To elucidate the role of TPO in megakaryopoiesis and platelet recovery after stem cell One patient with multiple myeloma received purified CD34 + peripheral blood stem cells. No difference was transplantation, we measured serum TPO levels in patients undergoing autologous PBSCT using a recently established observed in the kinetics of serum TPO levels between unfractionated and purified PBSCT. These observations sensitive sandwich enzyme-linked immunosorbent assay (ELISA). 16 suggest that TPO plays a critical role in the reconstitution of megakaryopoiesis and platelet production after PBSCT.

Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia

“…As reported, 3,4 an exponential increase in serum TPO level in response to thrombocytopenia was observed (log TPO ϭ 3.3-0.0035x; P Ͻ .001), and, as expected, 4-6 the confidence ellipse for patients with aplastic anemia (n ϭ 13) was superimposed with this regression line ( Figure 1A). Similar results were observed with the ellipse obtained with data from ALL patients at the time of diagnosis (n ϭ 42), and the regression line in these patients (log TPO ϭ 3.3-0.004x; P Ͻ .001) was not different from the regression line in controls.…”

“…1 In humans, high TPO levels are observed in patients with thrombocytopenia of central origin secondary to myeloablative treatment or MGK deficiency, whereas low TPO levels are observed in patients with increased platelet destruction thrombocytopenia. [2][3][4][5][6][7][8] We have previously observed a significant relationship between erythropoietin (EPO) and hemoglobin levels in children with cancer, indicating that, in contrast to anemia in adult cancer patients, anemia in children with cancer is associated with decreased erythropoiesis and not with inadequate erythropoietin production. 22 To evaluate the pathophysiology of thrombocytopenia associated with leukemia at diagnosis, we evaluated serum TPO levels in patients with ALL or AML.…”

Thrombopoietic cytokines in relation to platelet recovery after bone marrow transplantation

“…[19][20][21] However, the regulated production of TPO in therapy-induced thrombocytopenia is still being explored, especially in extrahepatic tissue such as marrow stroma. 22 Shimazaki et al 23 reported assay of serial serum TPO levels through the course of autotransplantation in nine patients, as did Ishida et al 24 for three allotransplant recipients. Similar to the results reported herein, a powerful inverse correlation between platelet counts and circulating TPO levels was recognized.…”

Changes in endogenous TPO levels during mobilization chemotherapy are predictive of CD34+ megakaryocyte progenitor yield and identify patients at risk of delayed platelet engraftment post-PBPC transplant

“…28,30 While some studies have shown an apparent correlation between TPO levels and platelet counts, standardization for interpatient variation was not considered since data points from multiple patients were pooled together in a single plot. 27,40 The importance of measuring the percentage change in TPO and its relationship to Mk mass and progenitor cell yield is illustrated in an idealized model (Figure 3). In the group II patient with a lower Mk reserve, there is a smaller percentage decrease from baseline to nadir following mobilization chemotherapy.…”